Fusion protein for targeting antigen-specific T cells and enhancing effector function of antigen-specific T cells

• Main Authors: CHENG XIANGRUI, WANG SHENGDIAN, LI YING, ZHENG XIAOXIAO, YANG NAIBO
• Format: Patent
• Language: Chinese; English
• Published: 12.04.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention provides a fusion protein targeting an antigen-specific T cell and enhancing the effector function of the antigen-specific T cell, relates to the technical field of bioengineering, and aims to solve the problems that the effective rate of an anti-PD-1 or PD-L1 antibody drug for treating tumors is low; in order to solve the problems that in the prior art, the side effect of IL-10 is large, according to the technical scheme, the fusion protein comprises an IL-10 coding gene and an anti-PD-1 antibody, the IL-10 coding gene and the anti-PD-1 antibody are connected to construct an anti-PD-1 antibody and IL-10 fusion protein expression vector, and the anti-PD-1 antibody and IL-10 fusion protein is obtained through transfection, expression in mammalian cells and purification. After the fusion protein of the PD-1 antibody and the IL-10 is input into a body, the blocking effect of the PD-1 antibody is played, meanwhile, the IL-10 is targeted to PD-1 positive anti-tumor T cells, particularly, the IL-10 pr